Skip to main content

Open Collaborative Model for Tuberculosis Lead Optimisation

Objective

"Early stage Drug Discovery efforts over the last 5 years have resulted in the identification of a number of promising lead compounds in the fight against TB. These leads need to be further progressed and optimised into candidates for pre-clinical development through the Drug Development progression cascade.

Three compound families are of particular interest: 1) InhA Inhibitors, 2) New potent whole cell anti-tubercular compounds with unknown mode of action and 3) new Beta-lactam/Beta-lactamase combinations for TB. A preclinical package is already in place for some of them, but further work is necessary for others in order to justify the progression of a single anti-tubercular family to the more resource intensive stages of preclinical and clinical development.

The project will encompass the parallel progression of the three compound families through: A) Lead Optimization Chemistry efforts and MoA studies (Genetic and Proteomic) for whole cell inhibitors, B) In vitro and in vivo evaluation of a new orally bioavailable Beta-lactam alone or in combination with a Beta-lactamase inhibitor to evaluate the sterilising potential of the new drug/s and C) the optimization of an InhA inhibitor for later preclinical development.

These efforts will yield candidate molecules for new ""information rich"" in vitro assays of antimycobacterial activity (artificial granuloma, activity against slow/non growing cells and activity against clinical isolates) as well as for in vivo safety and efficacy evaluation in different animal models of infection (acute and/or chronic). At this stage a single compound family will be prioritized.

Further studies will be performed assessing the potential for shortening treatment in stand alone therapy as well as in combination regimens both in vitro and in vivo. Finally a Clinical Development plan will be put in place for the selected candidate molecule."

Call for proposal

FP7-HEALTH-2010-single-stage
See other projects for this call

Funding Scheme

CP-FP - Small or medium-scale focused research project

Coordinator

GLAXOSMITHKLINE INVESTIGACION Y DESARROLLO SL
Address
C/ Severo Ochoa Numero 2 Parque Tecnologico De Mad
28760 Tres Cantos Madrid
Spain
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
EU contribution
€ 1 380 350,06
Administrative Contact
David Barros (Dr.)

Participants (13)

CELLZOME AG

Participation ended

Germany
EU contribution
€ 300 010
Address
Meyerhofstrasse 1
69117 Heidelberg
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Gerard Drewes (Dr.)
THE UNIVERSITY OF BIRMINGHAM
United Kingdom
EU contribution
€ 594 330
Address
Edgbaston
B15 2TT Birmingham
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Robert Fekete (Mr.)
UNIVERZA V LJUBLJANI
Slovenia
EU contribution
€ 684 112
Address
Kongresni Trg 12
1000 Ljubljana
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Stanislav Gobec (Prof.)
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
France
EU contribution
€ 621 414,20
Address
Rue De Tolbiac 101
75654 Paris
Activity type
Research Organisations
Administrative Contact
Frederic Altare (Dr.)
GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT NON PROFIT ORGANISATION
United States
EU contribution
€ 128 398,58
Address
Wall Street 40 24Th Floor
10005 New York
Activity type
Research Organisations
Administrative Contact
Martin Gerard Waters (Dr.)
THE FEDERAL STATE SCIENTIFIC INSTITUTION SAINT-PETERSBURG SCIENTIFIC RESEARCH PASTEUR INSTITUTE OF EPIDEMIOLOGY AND MICROBIOLOGY
Russia
EU contribution
€ 124 200
Address
Mira Street 14
197101 Saint Petersburg
Activity type
Research Organisations
Administrative Contact
Olga Narvskaya (Dr.)
NANOLOGICA AB
Sweden
EU contribution
€ 253 354
Address
Drottning Kristinas Väg 45
114 28 Stockholm
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Moa Lihammar Fd Eklund (Dr.)
CELLZOME GMBH
Germany
Address
Meyerhofstrasse 1
69117 Heidelberg
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Gerard Drewes (Dr.)
UNIVERSITE PIERRE ET MARIE CURIE - PARIS 6
France
EU contribution
€ 578 795,20
Address
Place Jussieu 4
75252 Paris
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Arthur Michel (Dr.)
ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE
Switzerland
EU contribution
€ 545 884,96
Address
Batiment Ce 3316 Station 1
1015 Lausanne
Activity type
Higher or Secondary Education Establishments
Administrative Contact
John Mckinney (Prof.)
FEDERAL STATE INSTITUTION SAINT PETERSBURG RESEARCH INSTITUTE OF PHTHISIOPULMONOLOGY OF THE FEDERAL AGENCY FOR HIGH TECHNOLOGY MEDICAL AID
Russia
EU contribution
€ 124 200
Address
Ligovsky Prospekt 2-4
193063 Saint Petersburg
Activity type
Research Organisations
Administrative Contact
Boris Vishnevskiy (Prof.)
INSTITUT PASTEUR KOREA
South Korea
Address
Hawolgok Dong, Seongbuk Gu 39-1
136 791 Seoul
Activity type
Research Organisations
Administrative Contact
Jonathan Cechetto (Dr.)
TASK FOUNDATION NPC
South Africa
EU contribution
€ 22 380
Address
M2 Karl Bremer Hospital Mike Pienaar Boulevard Belleville
7530 Cape Town
Activity type
Other
Administrative Contact
Jaco Swart (Mr.)